What is the BNT-162b2 coronavirus disease 2019 (COVID-19) vaccine?
BNT-162b2 (Pfizer) is derived from mRNA method of technology. It is a nucleoside-modified messenger RNA (modRNA) vaccine. BNT-162b2 vaccine contains RBD i.e. receptor-binding antigen of SARS-CoV-2. Dose series = 2-dose series. Both doses have difference of 21 days. Vaccine efficacy = 95% Safety concerns = none